Laboratory Studies Confirm the Effectiveness of BETADINE® Gargle and Mouthwash Against COVID-19 Virus
30.6.2020 17:57:00 EEST | Business Wire | Press release
Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, has confirmed the effectiveness of BETADINE® Gargle and Mouthwash against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. BETADINE® is manufactured and distributed in Malaysia by Mundipharma.
BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) under established European (EN14476) methodology and standards. The testing demonstrated strong in-vitro virucidal activity, with the tested products killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.
The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
“Laboratory testing has shown that BETADINE® Gargle and Mouthwash is effective against COVID-19 and could contribute to our ongoing efforts to keep people and communities safe,” said Dr Pouya Hassandarvish, the Lead Investigator of the Study and the postdoctoral fellow researcher at TIDREC, University of Malaya.
“These results confirm our view that BETADINE® Gargle and Mouthwash, used appropriately and in conjunction with other preventative treatment options including PPE, could play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, Mundipharma CEO.
“It also provides the medical and dental community with a science-based assurance that they are using a product that is specifically studied against COVID-19,” he added.
Previously, BETADINE® antiseptic products containing Povidone-iodine (PVP-I) have been proven effective against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals and homes.
About TIDREC
TIDREC serves as a focal point for national and international collaborative research for academic institutions and research industries in Malaysia. TIDREC also emphasizes on education and development of human skills. By advocating safe laboratory science, TIDREC aspires to be an internationally recognized centre of excellence in tropical infectious diseases research and education that serves the health needs of global communities.
TIDREC was the first research centre in the country to install fully certified modular biosafety level 2 & 3 laboratories for research involving highly virulent pathogens. TIDREC is also the only centre currently operating a mock biosafety level 3 training facility. The centre also houses the WHO Collaborating Centre for Arbovirus Reference & Research. The centre offer services such as drug screening, validation test for diagnostic kits and research collaboration on vector-borne diseases.
TIDREC mission is to advance knowledge by focusing on research in neglected tropical infectious diseases that have a potential impact on the global community.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About BETADINE®
The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include Povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® Povidone-iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.
®: BETADINE is a registered trademark of Mundipharma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005731/en/
Contact information
For further information please contact:
Alice George
Principal Consultant
AG Global Communications
A-13-4, Tiara Faber
456, Jalan Desa Utama
Taman Desa
58100 Kuala Lumpur
Malaysia
Email: alice.agcomm@gmail.com
Mobile: +60196008157
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 11:00:00 EEST | Press release
It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefore shortening the timeline to Q-Day. This has led prominent experts to estimate today’s encryption may be broken as-soon-as the next three years. It’s against this backdrop that the International Organisation for Standardisation (ISO) has included the Classic McEliece algorithm as part of its standard for Asymmetric Ciphers (ISO/IEC 18033-2). Organisations from ISO’s 177 member states can now upgrade to Classic McEliece using an international s
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 10:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI ® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 10:00:00 EEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
SES, Airbus and Dutch Municipality of Noordwijk to Build Satellite Optical Ground Station for EAGLE-115.7.2026 09:50:00 EEST | Press release
SES, a space solutions company, jointly with Airbus Netherlands B.V. signed a ground lease agreement with the Dutch municipality of Noordwijk for a plot at the NL Space Campus, next to the European Space Agency’s (ESA) technical center ESTeC. The facility will host a dedicated optical ground station (OGS) to communicate with the EAGLE-1 satellite and receive quantum safe keys via laser technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714786947/en/ Breaking the ground of the EAGLE-1 Optical Ground Station, Municipality of Noordwijk, the Netherlands. Pictured left to right: Pim van Strien, Alderman for the Municipality of Noordwijk; Rob Postma, President and Managing Director, Airbus Netherlands; Alan Kuresevic, Managing Director, SES Techcom, SES. The station, to be built by Airbus for SES, will consist of a control room, alongside a dome housing an ultra-precise telescope to track satellites, required for the la
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend15.7.2026 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company previously extended that submission deadline to June 30, 2026, and has now further extended that submission deadline to December 31, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before December 31, 2026 in order to facilitate paym
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
